- Research article
- Open Access
- Open Peer Review
Celastrol targets mitochondrial respiratory chain complex I to induce reactive oxygen species-dependent cytotoxicity in tumor cells
BMC Cancervolume 11, Article number: 170 (2011)
Celastrol is an active ingredient of the traditional Chinese medicinal plant Tripterygium Wilfordii, which exhibits significant antitumor activity in different cancer models in vitro and in vivo; however, the lack of information on the target and mechanism of action of this compound have impeded its clinical application. In this study, we sought to determine the mode of action of celastrol by focusing on the processes that mediate its anticancer activity.
The downregulation of heat shock protein 90 (HSP90) client proteins, phosphorylation of c-Jun NH2-terminal kinase (JNK), and cleavage of PARP, caspase 9 and caspase 3 were detected by western blotting. The accumulation of reactive oxygen species (ROS) was analyzed by flow cytometry and fluorescence microscopy. Cell cycle progression, mitochondrial membrane potential (MMP) and apoptosis were determined by flow cytometry. Absorption spectroscopy was used to determine the activity of mitochondrial respiratory chain (MRC) complexes.
Celastrol induced ROS accumulation, G2-M phase blockage, apoptosis and necrosis in H1299 and HepG2 cells in a dose-dependent manner. N-acetylcysteine (NAC), an antioxidative agent, inhibited celastrol-induced ROS accumulation and cytotoxicity. JNK phosphorylation induced by celastrol was suppressed by NAC and JNK inhibitor SP600125 (SP). Moreover, SP significantly inhibited celastrol-induced loss of MMP, cleavage of PARP, caspase 9 and caspase 3, mitochondrial translocation of Bad, cytoplasmic release of cytochrome c, and cell death. However, SP did not inhibit celastrol-induced ROS accumulation. Celastrol downregulated HSP90 client proteins but did not disrupt the interaction between HSP90 and cdc37. NAC completely inhibited celastrol-induced decrease of HSP90 client proteins, catalase and thioredoxin. The activity of MRC complex I was completely inhibited in H1299 cells treated with 6 μM celastrol in the absence and presence of NAC. Moreover, the inhibition of MRC complex I activity preceded ROS accumulation in H1299 cells after celastrol treatment.
We identified ROS as the key intermediate for celastrol-induced cytotoxicity. JNK was activated by celastrol-induced ROS accumulation and then initiated mitochondrial-mediated apoptosis. Celastrol induced the downregulation of HSP90 client proteins through ROS accumulation and facilitated ROS accumulation by inhibiting MRC complex I activity. These results identify a novel target for celastrol-induced anticancer activity and define its mode of action.
Celastrol, a quinone methide triterpene, is an active component of Tripterygium Wilfordii. Celastrol has been used in the treatment of autoimmune and neurodegenerative diseases for its antioxidative and anti-inflammatory effects [1–4]. Recently, celastrol was found to exhibit significant anticancer activities in vitro and in vivo, including the induction of apoptosis in different cancer cells [5–9], synergistically enhancing the cytotoxicity of other chemotherapeutic agents [10–12], and inhibiting the growth of glioma, melanoma and prostate cancer in nude mice [6, 13, 14]. However, the target and mechanism of action of celastrol are not completely clear.
Celastrol has been identified as a novel inhibitor of heat shock protein 90 (HSP90) and displays anticancer activity by inducing the degradation of HSP90 client proteins [7, 9, 15–17]. In addition, celastrol has been reported to be a potent inhibitor of proteasomes and induce cytotoxicity in glioma and prostate cancer models in vivo and in vitro [8, 13]. Several other molecular targets have been proposed to explain the anticancer effects of celastrol, including NFκB [10, 18, 19], topoisomerase II , and xc-Cystine/Glutamate antiporter . Although these targets positively correlate with celastrol-induced cytotoxicity, it is not clear which, if any, is the principal mediator of the antitumor activity of celastrol. As celastrol is moved into clinical studies, it is important to gain a better understanding of its target and mechanism.
Reactive oxygen species (ROS) are formed mainly by the interaction of oxygen molecules with electrons that escape from the mitochondrial respiratory chain (MRC) [21, 22]. ROS are scavenged by antioxidative proteins, including catalase, superoxide dismutase (SOD) and thioredoxin (Trx) [23, 24]. Inhibiting the activity of MRC complexes increases the leakage of electrons by blocking the electron transfer chain, thus promoting ROS production [22, 25]. The downregulation of antioxidative proteins decreases ROS clearance and facilitates ROS accumulation . ROS have been reported to regulate signal transduction and gene expression and to induce oxidative damage of nucleic acids, proteins, and lipids [27–29]. Therefore, ROS play an important role in the processes that determine cell fate such as proliferation, differentiation and apoptosis [30–32]. Although low levels of ROS have been reported to promote cell survival and proliferation, the accumulation of ROS induces mitochondrial-mediated apoptosis by facilitating the release of cytochrome c (Cyt c) and apoptosis-inducing factor [30, 32, 33].
In this study, we demonstrate that celastrol-induced cytotoxicity, including cell growth inhibition, cell cycle arrest and apoptotic and necrotic cell death, was mediated by ROS. Moreover, the downregulation of HSP90 client proteins induced by celastrol was also ROS-dependent. The accumulation of ROS leds to activation of c-Jun NH2 terminal kinase (JNK), initiation of the mitochondrial apoptotic pathway and induction of cell death. The mechanism by which celastrol induces ROS accumulation involves the inhibition of MRC complex I activity, but not the expression of antioxidative proteins. These results present a new target and mechanism for celastrol-induced cytotoxicity.
Cells and reagents
H1299 and HepG2 cells were obtained from the American Tissue Culture Collection (Manassas, VA). Cells were cultured with Dulbecco's modified Eagle medium (Gibco, Grand Island, NY) containing 10% fetal bovine serum (FBS, HyClone, Logan, UT). Celastrol was purchased from Calbiochem (San Diego, CA) and dissolved in DMSO. N-acetylcysteine and 17-allylamino-17-demethoxygeldanamycin were purchased from Sigma (St Louis, MO). SP600125 was purchased from LC laboratories (Worburn, MA). Z-VAD-FMK was purchased from R&D Systems (Minneapolis, MN, USA).
Cell viability assay
Cells were collected by trypsinization and incubated with 0.4% trypan blue for 3 minutes at room temperature. The viable (unstained) cells were counted and used to calculate viability.
Cell cycle analysis
50,000 cells were fixed with 70% ethanol containing 1% FBS at -20°C overnight, and then incubated with RNase A (20 μg/mL) at 37°C for 30 minutes, stained with propidium iodide (100 μg/mL) for 10 minutes, and then analyzed by flow cytometry (FACSCalibur, BD, USA) and ModFit LT software (FACSCalibur, BD, USA). For each measurement, 20,000 cells were analyzed and the representative measurements were shown.
Apoptosis and necrosis analysis
Apoptosis and necrosis were determined by a Annexin V-FITC Kit (Roche, Indianapolis, IN). H1299 and HepG2 cells were collected by trypsinization. After washed with PBS, cells were stained with annexin V-FITC and propidium iodide, and then the apoptosis and necrosis were determined by flow cytometry (FACSCalibur) and CELLQuest software (FACSCalibur). For each measurement, 20,000 cells were analyzed and the representative measurements were shown.
Measurement of mitochondrial membrane potential
The mitochondrial membrane potential was measured with a Mitochondrial Membrane Potential Assay Kit with JC-1 (Beyotime biotechnologies, Jiangsu, China) according to the manufacturer's instruction. Briefly, 50,000 cells were collected by trypsinization and incubated with JC-1 for 20 minutes at 37°C in the dark. The stained cells were washed with ice-cold working solution twice and then analyzed by flow cytometry (FACSCalibur) and CELLQuest software (FACSCalibur). 20,000 cells were analyzed in each measurement. JC-1 aggregates in the polarized mitochondrial matrix and forms J-aggregates, which emit red fluorescence at 595 nm when excited at 525 nm. However, JC-1 cannot aggregate in the depolarized mitochondrial matrix and exists as JC-1 monomers, which emit green fluorescence at 525 nm when excited at 485 nm. Mitochondrial depolarization is indicated by a decrease in the red/green fluorescence intensity ratio.
ROS were measured by a Reactive Oxygen Species Assay Kit (Applygen Technologies, Beijing, China). Briefly, cells were incubated with 3 μM DCFH-DA for 40 minutes at 37°C in the dark, and ROS were determined by fluorescence microscopy or flow cytometry (FACSCalibur) at an excitation wavelength of 480 nm and an emission wavelength of 525 nm. More than 3 fields were observed by fluorescence microscope and 20,000 stained cells were analyzed with flow cytometry in each measurement. The ROS fold was calculated based on the mean geometry fluorescence determined by flow cytometry and shown as a histogram.
Immunoprecipitation and western blot analysis
Immunoprecipitation and western blotting were performed according to the method described by Yu . For immunoprecipitation experiments, cells were lysed in TNESV buffer containing 50 mM Tris (pH 7.5), 2 mM EDTA, 100 mM NaCl, 2% Nonidet P-40 (NP-40), 1 mM Na3VO4 and cocktail (1 tablet/10 mL solution, Roche, Indianapolis, USA) at 4°C for 30 minutes. Cell lysates were centrifuged at 10,000 g to remove cellular debris. Protein concentration in the lysate was quantified with a Bicinchoninic Acid (BCA) Protein Assay Kit (Pierce, Rockford, IL, USA). Approximately 500 μg total proteins was incubated with 2 μg heat shock protein 90 antibody (Stressgen, Victoria, British Columbia, Canada) at 4°C for 12 h, after which 20 μL of protein A/G Plus Agarose (Santa Cruz, CA, USA) was added into the mixture and incubated for 2 h at 4°C. Agarose-antibody-protein complexes were washed one time with lysis buffer and two times with PBS. The immune complexes were resuspended in 20 μL of Laemmli Buffer (Bio-Rad Laboratories, CA, USA) and boiled for 5 minutes. The samples were analyzed by western blotting.
For western blotting experiments, cells were lysed in Laemmli Buffer (Bio-Rad Laboratories) and protein concentration in the lysate was quantified by a BCA Protein Assay Kit (Pierce,). Fifty micrograms of total protein was subjected to SDS-PAGE and transferred onto a PVDF membrane. The membrane was blotted with primary antibodies for 12-15 h at 4°C and incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. Proteins were detected using a SuperEnhanced Chemiluminescence Detection Kit (Applygen Technologies). The antibodies used in the study were anti-PARP, cleaved caspase 3, caspase 9, phospho-JNK, JNK, AKT, epidermal growth factor receptor, heat shock protein 90, CDK4 and Thioredoxin (Cell Signaling, Beverly, MA); anti-catalase (Abcam, Cambridge, MA); anti-Bad (Transduction Laboratories, KY); anti-cytochrome c, superoxide dismutase and Cdc37 (Santa Cruz,) and anti-β-actin (Oncogene, Boston).
The mitochondria were isolated with a Mitochondrial Isolation Kit (Applygen Technologies). Fifty million cells were resuspended with ice-cold Mito-Cyto isolation buffer and homogenized with the grinder. Homogenate was centrifuged at 800 g for 10 minutes at 4°C. The supernatants were collected in a new tube, and centrifuged at 10,000 g for 10 minutes at 4°C. The supernatant and pellet were saved as cytosolic fraction and intact mitochondria, respectively. The intact mitochondria were lysed with Laemmli Buffer (Bio-Rad Laboratories) to extract mitochondrial protein. The alteration of Bad and cytochrome c in mitochondria and cytoplasm were analyzed by western blotting.
Measurement of MRC Complexes Activity
The activity of MRC complexes was determined with Mitochondrial Respiratory Chain Complexes Activity Assay Kits (Genmed Scientifics, Shanghai, China). Briefly, the isolated mitochondria were resuspended with the Mito-Cito buffer (Applygen Technologies), frozen at -70°C and thawed at 37°C three times to extract the mitochondrial proteins. The protein concentration in the lysate was determined using the BCA Protein Assay Kit (Pierce, Rockford) and diluted to 0.1 μg/μL. The absorbance was determined on a Smartspec™ Plus spectrophotometer (Bio-Rad). The activity of complex I-linked NADH-ubiquinone reductase was determined by measuring the reduction of ubiquinone to ubiquinol, which leads to a decrease in absorbance of NADH at 340 nm. The activity was measured with or without rotenone, a specific inhibitor of NADH-ubiquinone reductase. The specific activity of complex I was calculated by subtracting the rotenone-nonsensitive activity from the total activity and is expressed as μM NADH mg/min. Complex II-linked succinate-ubiquinone reductase activity was determined by measuring the reduction of 2,6-dichlorophenolindophenol (DCIP), which can be monitored at 600 nm. The activity is expressed as μM DCIP mg/min. Complex III-linked ubiquinol cytochrome c reductase activity was determined by monitoring the reduction of cytochrome c by the electrons donated from ubiquinol, which can be monitored at 550 nm. The activity was measured with or without antimycin A, a specific inhibitor of ubiquinol cytochrome c reductase. The specific activity of complex III was calculated by subtracting the antimycin A-nonsensitive activity from the total activity and is expressed as μM CoQH2 mg/min. Complex IV-linked cytochrome c oxidoreductase activity was determined by measuring the oxidation of cytochrome c, which can be monitored at 550 nm. The activity was expressed as μM Cyt c mg/min. All measurements were performed in triplicate.
Statistical significance was analyzed by ANOVA test or unpaired ttest. Statistical significance was defined as p < 0.01. All experiments were repeated at least three times, and data are expressed as the mean ± SD (standard deviation) from a representative experiment.
Celastrol initiates ROS accumulation and mediates cytotoxicity in a dose-dependent manner
To determine the role of ROS in mediating celastrol-induced cytotoxicity, we first measured ROS levels in H1299 and HepG2 cells after celastrol exposure. As shown in Figure 1A, celastrol increased ROS levels in a dose-dependent manner in both H1299 and HepG2 cells. Celastrol also reduced cell viability in both H1299 and HepG2 cells in a dose-dependent manner (Figure 1B). Celastrol arrested cell cycle in both cell lines, and the G2-M phase ratio rose from 15 ± 1.6% to 41 ± 3.1% in H1299 cells and 15 ± 1.8% to 34 ± 3.5% in HepG2 cells after 24 h of treatment with 6 μM celastrol (Figure 1C). The results of annexin V-FITC and propidium iodide (PI) staining showed that celastrol induced apoptotic and necrotic cell death in a dose-dependent manner, and the percent of cell death (apoptosis and necrosis) was 41 ± 4.1% in H1299 cells and 22 ± 2.5% in HepG2 cells treated with 6 μM celastrol for 24 h (Figure 1D). Therefore, ROS levels positively correlate with cell death and growth arrest induced by celastrol. Moreover, scavenging of ROS by the antioxidative agent N-acetylcysteine (NAC) inhibited celastrol-induced decrease in cell viability, cell cycle arrest and cell death (Figure 1). As ROS have been reported to mediate the cytotoxicity induced by some cytotoxic agents [22, 25], we assumed that ROS played a critical role in mediating celastrol-induced cytotoxicity as well.
Celastrol-induced decrease of HSP90 client proteins is mediated by ROS
Celastrol has been identified as a novel HSP90 inhibitor and mediates cytotoxicity by facilitating the degradation of HSP90 client proteins [7, 9, 15–17]. Thus, we determined whether ROS were involved in mediating the decline of HSP90 client proteins induced by celastrol. Levels of the HSP90 client proteins including AKT, epidermal growth factor receptor (EGFR) and CDK4 were all decreased following celastrol treatment in H1299 cells (Figure 2A). However, the decrease of HSP90 client proteins induced by celastrol was completely inhibited by NAC (Figure 2A). To determine whether the decline of HSP90 client proteins induced by celastrol was dependent on apoptosis, we analyzed the effect of celastrol on HSP90 client protein expression in the absence and presence of Z-VAD-FMK (Z-VAD), a pan-caspase inhibitor. As shown in Figure 2B, 50 μM Z-VAD significantly decreased the cleavage of PARP (apoptosis marker) induced by celastrol, indicating that Z-VAD inhibited celastrol-induced apoptosis. However, Z-VAD had no significant effect on celastrol-induced decrease of HSP90 client proteins including EGFR, AKT and CDK4, suggesting that celastrol-induced decrease of HSP90 client proteins is not dependent on apoptosis. By using a GST pull-down assay, a previous study has reported that celastrol could disrupt the HSP90/Cdc37 complex ; however, we did not observe that the interaction between endogenous HSP90 and Cdc37 was disrupted by celastrol in H1299 cells (Figure 2C). In addition, we compared the effect of NAC in reversing the decrease of HSP90 client proteins induced by 17-allylamino-17-demethoxygeldanamycin (17-AAG), a classic HSP90 inhibitor, with that induced by celastrol. Both 17-AAG and celastrol induced the depletion of HSP90 client proteins including AKT and EGFR whereas NAC blocked celastrol-induced depletion of ATK and EGFR but had no effect on 17-AAG-induced HSP90 client protein degradation (Figure 2D). These data indicate that celastrol-induced inhibition of HSP90 chaperone function is mediated by ROS.
Celastrol induces ROS accumulation by inhibiting the activity of MRC complex I
ROS play a critical role in mediating the cytotoxicity induced by celastrol, but the targets by which celastrol induces ROS accumulation are unknown. To identify the targets for celastrol-induced ROS accumulation, we first measured ROS levels in H1299 cells at different time points after celastrol exposure. As shown in Figure 3A, celastrol induced time-dependent ROS accumulation in H1299 cells, and ROS levels increased 7.7 ± 0.7 times after 1 h of celastrol treatment. The downregulation of antioxidative proteins results in ROS accumulation ; therefore, we investigated the effect of celastrol on the expression of antioxidative proteins, including catalase, SOD, and Trx. Celastrol had no significant effect on SOD but slightly downregulated catalase and Trx expression (Figure 3B). However, the downregulation of catalase and Trx was completely inhibited by NAC (Figure 3B). Therefore, celastrol does not cause ROS accumulation by downregulating the antioxidative proteins SOD, catalase, and Trx.
Inhibiting the activity of MRC complexes promotes ROS production . Therefore, we speculated that celastrol may induce ROS accumulation by inhibiting MRC complex activity. We detected the effect of celastrol on different MRC complexes. Celastrol completely inhibited MRC complex I activity but increased MRC complex IV activity (Figure 3C), indicating that complex I, but not complex IV, may be the target of celastrol in mediating ROS accumulation. The activity of MRC complex II and III decreased in H1299 cells treated with celastrol; however, NAC reversed the inhibition (Figure 3C), indicating that complex II and III are not likely targets of celastrol for ROS accumulation. In addition, MRC complex I activity was completely inhibited as early as 30 minutes after celastrol exposure (Figure 3D), which precedes ROS accumulation. In contrast, the activity of MRC complex II, III and IV did not significantly decrease after 30 or 60 minutes of treatment with celastrol (Figure 3D), further confirming that complex I is the target of celastrol in promoting ROS production.
Celastrol-induced activation of the mitochondrial apoptotic pathway is mediated by ROS
Because celastrol induced apoptosis in a dose-dependent manner (Figure 1D), we further investigated the effect of celastrol on mitochondria. The mitochondrial membrane potential (MMP) was measured using a JC-1 fluorescent probe, and the JC-1 red/green fluorescence intensity ratio was used to represent MMP. As shown in Figure 4A, celastrol treatment resulted in a dose-dependent decrease in MMP in H1299 cells. The JC-1 red/green fluorescence intensity ratio in H1299 cells treated with 6 μM celastrol for 24 h decreased to 2 ± 0.2%, indicating that celastrol significantly induced dysfunction of mitochondria. As before, NAC inhibited the decrease of MMP induced by celastrol (Figure 4A), indicating that ROS were involved in mediating mitochondrial depolarization. Moreover, as shown in Figure 4B, NAC could completely block the cleavage of PARP, caspase 9, and caspase 3 in H1299 cells treated with celastrol. These data are consistent with celastrol induced mitochondrial-mediated apoptosis through ROS accumulation.
Celastrol activates JNK through ROS accumulation, which plays a critical role in mediating the activation of mitochondrial apoptotic pathway
As the stress-activated protein kinase, JNK can be activated by oxidative stress induced by accumulated ROS [35, 36]. Activated JNK initiates the mitochondrial apoptotic pathway by mediating the activation and mitochondrial translocation of proapoptotic proteins including Bax and Bad [37–39]. We determined the effect of celastrol on JNK activation. As shown in Figure 4C, celastrol increased the level of JNK phosphorylation in a dose-dependent manner whereas NAC completely inhibited celastrol-induced JNK phosphorylation, demonstrating that JNK was activated by celastrol-induced ROS accumulation. The results of annexin V-FITC and PI staining showed that JNK inhibitor SP600125 (SP) significantly inhibited celastrol-induced apoptosis and necrosis. The percentage of cell death (apoptosis and necrosis) was 43 ± 4.1% in cells treated with celastrol and 11 ± 1.2% in cells treated with celastrol and SP (Figure 4D).
We further determined the mechanism by which JNK mediates celastrol-induced cell death. As shown in Figure 5A, SP did not suppress celastrol-induced ROS accumulation, indicating that SP does not inhibit celastrol-induced cell death by suppressing ROS accumulation. However, SP significantly inhibited celastrol-induced depolarization of mitochondria. The JC-1 red/green fluorescence intensity ratio was 7 ± 1.4% and 68 ± 4.2% in H1299 cells treated with 6 μM celastrol alone and 6 μM celastrol with SP for 24 h, respectively (Figure 5B). Moreover, SP inhibited celastrol-induced JNK phosphorylation and cleavage of PARP, caspase 9 and caspase 3 (Figure 5C). Furthermore, SP significantly inhibited mitochondrial translocation of Bad and cytoplasmic release of Cytochrome c induced by celastrol (Figure 5D). Therefore, ROS-induced JNK activation played a crucial role in initiating mitochondria-mediated apoptosis of H1299 cells treated with celastrol.
Celastrol displays significant anti-cancer activity in vivo and in vitro in various cancer models [5, 7, 13, 18], but the precise target and mechanism are not clear. In this study, we demonstrate that celastrol induces cytotoxicity by causing ROS accumulation. Accumulated ROS inhibited HSP90 function, activated JNK, and induced cell cycle arrest and apoptotic and necrotic cell death. The effects of celastrol on ROS accumulation and apoptosis were observed in both lung cancer cells (H1299) and hepatoma cells (HepG2). Therefore, we conclude that ROS represent a novel intermediate in mediating celastrol-induced cytotoxicity.
As the stress-activated protein kinase, JNK plays a critical role in mediating apoptotic cell death . It has been previously reported that celastrol activates JNK by suppressing the transcriptional activity of ATF2 . However, we observed that JNK was activated by celastrol-induced ROS accumulation. Recent studies have indicated that ROS play important roles in regulating both normal cellular processes, such as proliferation, differentiation and migration, and disease progression, such as cancer [30–33]. Accumulated ROS have been identified as the key intermediate for the cytotoxicity induced by many chemotherapeutic agents [22, 38, 40]. In cells, many antioxidative enzymes respond to scavenge ROS and maintain low levels of cellular ROS. Among the antioxidative system, catalase, SOD and Trx are the main proteins involved in ROS clearance, and some chemotherapeutic agents induce ROS-dependent cytotoxicity by downregulating the expression of these antioxidative proteins [23, 24, 41, 42]. However, in our study, we found that celastrol did not affect the expression of SOD and only slightly downregulated catalase and Trx expression at a high dose, which was inhibited by NAC. Therefore, we concluded that celastrol did not induce ROS-dependent cytotoxicity by inducing dysfunction of the antioxidative system. Though many enzymes, including NADPH oxidase, cytochrome c oxidase and lipoxygenase, respond to ROS production, the main source of ROS generation is the MRC . Some cytotoxic agents, such as rotenone, have been shown to induce ROS-dependent cytotoxicity by targeting MRC complex I [22, 25]. In this study, we found that after exposure of 6 μM celastrol for 30 minutes, the cellular activity of MRC complex I was completely inhibited (Figure 3C). This inhibitory effect was not reversed by NAC, demonstrating that inhibition of MRC complex I activity contributes to celastrol-induced ROS accumulation. However, whether celastrol can directly inhibit MRC complex I activity requires further study.
Previous studies have reported that celastrol inhibits lipid peroxidation in rat liver mitochondrial membranes induced by ADP and Fe2+ [43, 44]. These results conflict with our results that celastrol induces oxidative stress by causing ROS accumulation in H1299 and HepG2 cells. It is possible that this discrepancy may be attributed to the difference between normal tissues (rat liver mitochondrial membrane) and cancer cells (non-small lung cancer cells and hepatoma cells). Celastrol has been reported to protect neuronal cells from cytotoxicity by increasing the expression of heat shock proteins and suppressing the release of inflammatory intermediates [1, 3]. However, celastrol inhibits pro-inflammatory cytokine secretion and promotes expression of heat shock proteins at nanomolar concentrations whereas the cytotoxic concentration of celastrol for neuronal cells is approximately 1 μM [2, 3]. Therefore, it seems that the protective or cytotoxic role of celastrol is dependent on the dose.
HSP90 is a highly abundant molecular chaperone that maintains the stability and activity of multiple kinases, transcription factors and steroid receptors [45, 46]. The classic HSP90 inhibitors, such as geldanamycin (GA) and 17-AAG, inhibit HSP90 chaperone function by competing with ATP for the ATP-binding pocket of HSP90 and then facilitate the degradation of HSP90 client proteins . Celastrol has been identified as an inhibitor of HSP90 and displays cytotoxicity by inducing the degradation of HSP90 client proteins [7, 9, 16]. Consistent with these previous reports, we found that celastrol induced the downregulation of EGFR, AKT and CDK4. However, we found that celastrol-induced decrease of HSP90 client proteins was inhibited by scavenging ROS. Recently, GA and 17-AAG have been shown to promote superoxide generation [48, 49], but it has been suggested that oxidative stress alone is insufficient to disrupt HSP90 binding to its client proteins . Consistent with this result, our data also show that NAC could not block the degradation of AKT and EGFR induced by 17-AAG. Compared with 17-AAG, ROS obviously play a key role in mediating the downregulation of HSP90 client proteins induced by celastrol.
Although a previous study attributed the mechanism for celastrol-induced degradation of HSP90 client proteins to the disruption of HSP90/Cdc37 complex , we did not find that the interaction of HSP90 and Cdc37 was disrupted by 6 μM celastrol, either in the absence or in the presence of NAC. Another report also verified that 5 μM celastrol had no effect on the interaction of HSP90 and Cdc37; only 10 μM celastrol showed the ability to decrease the interaction of HSP90 and Cdc37 . Therefore, celastrol-induced disruption of the HSP90/Cdc37 complex appears to be highly dose-dependent. Because the dose required to disrupt the HSP90/Cdc37 complex is higher than the IC50 , it is not clear whether the cytotoxic effect of celastrol is due to the disruption of the interaction between HSP90 and Cdc37. In view of our finding that 6 μM celastrol did not disrupt the interaction between HSP90 and Cdc37, we conclude that ROS mediate the degradation of HSP90 client proteins through other pathways. It is possible that aberrant ROS cause oxidative damage to proteins, which promotes their degradation .
In conclusion, we demonstrate that celastrol targets MRC complex I and induces ROS accumulation and that accumulated ROS act as the key intermediate that induces cell cycle arrest, inhibits HSP90 chaperone function, downregulates HSP90 client proteins, activates JNK and initiates apoptotic and necrotic cell death (Figure 6). Therefore, the present study identifies a new target and a new mechanism for the anti-cancer activity displayed by celastrol.
heat shock protein 90
c-Jun NH2-terminal kinase
mitochondrial membrane potential
mitochondrial respiratory chain
poly (ADP-ribose) polymerase
reactive oxygen species
Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C: Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2001, 25: 1341-1357. 10.1016/S0278-5846(01)00192-0.
Jung HW, Chung YS, Kim YS, Park YK: Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-kappaB in LPS-stimulated BV-2 microglial cells. Exp Mol Med. 2007, 39: 715-721.
Chow AM, Brown IR: Induction of heat shock proteins in differentiated human and rodent neurons by celastrol. Cell Stress Chaperones. 2007, 12: 237-244. 10.1379/CSC-269.1.
Kim DH, Shin EK, Kim YH, Lee BW, Jun JG, Park JH, Kim JK: Suppression of inflammatory responses by celastrol, a quinone methide triterpenoid isolated from Celastrus regelii. Eur J Clin Invest. 2009, 39: 819-827. 10.1111/j.1365-2362.2009.02186.x.
Nagase M, Oto J, Sugiyama S, Yube K, Takaishi Y, Sakato N: Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem. 2003, 67: 1883-1887. 10.1271/bbb.67.1883.
Abbas S, Bhoumik A, Dahl R, Vasile S, Krajewski S, Cosford ND, Ronai ZA: Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin Cancer Res. 2007, 13: 6769-6778. 10.1158/1078-0432.CCR-07-1536.
Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, Sun D: A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther. 2008, 7: 162-170. 10.1158/1535-7163.MCT-07-0484.
Ge P, Ji X, Ding Y, Wang X, Fu S, Meng F, Jin X, Ling F, Luo Y: Celastrol causes apoptosis and cell cycle arrest in rat glioma cells. Neurol Res. 2010, 32: 94-100. 10.1179/016164109X12518779082273.
Lu Z, Jin Y, Qiu L, Lai Y, Pan J: Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett. 2010, 290: 182-191. 10.1016/j.canlet.2009.09.006.
He D, Xu Q, Yan M, Zhang P, Zhou X, Zhang Z, Duan W, Zhong L, Ye D, Chen W: The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer. 2009, 9: 343-10.1186/1471-2407-9-343.
Zhu H, Ding WJ, Wu R, Weng QJ, Lou JS, Jin RJ, Lu W, Yang B, He QJ: Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol. Cancer Invest. 2010, 28: 23-32. 10.3109/07357900903095664.
Chen M, Rose AE, Doudican N, Osman I, Orlow SJ: Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Mol Cancer Res. 2009, 7: 1946-1953. 10.1158/1541-7786.MCR-09-0243.
Yang H, Chen D, Cui QC, Yuan X, Dou QP: Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 2006, 66: 4758-4765. 10.1158/0008-5472.CAN-05-4529.
Huang Y, Zhou Y, Fan Y, Zhou D: Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett. 2008, 264: 101-106. 10.1016/j.canlet.2008.01.043.
Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D: Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J Biol Chem. 2009, 284: 35381-35389. 10.1074/jbc.M109.051532.
Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J, Hahn WC, Chiosis G, Golub TR: Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006, 10: 321-330. 10.1016/j.ccr.2006.09.005.
Chadli A, Felts SJ, Wang Q, Sullivan WP, Botuyan MV, Fauq A, Ramirez-Alvarado M, Mer G: Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillization of the Co-chaperone p23. J Biol Chem. 2010, 285: 4224-4231. 10.1074/jbc.M109.081018.
Sethi G, Ahn KS, Pandey MK, Aggarwal BB: Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood. 2007, 109: 2727-2735.
Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K, Hong YS, Lee JJ: Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol. 2006, 72: 1311-1321. 10.1016/j.bcp.2006.08.014.
Pham AN, Blower PE, Alvarado O, Ravula R, Gout PW, Huang Y: Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines. J Pharmacol Exp Ther. 2010, 332: 949-958. 10.1124/jpet.109.162248.
Poyton RO, Ball KA, Castello PR: Mitochondrial generation of free radicals and hypoxic signaling. Trends Endocrinol Metab. 2009, 20: 332-340. 10.1016/j.tem.2009.04.001.
Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA, Robinson JP: Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem. 2003, 278: 8516-8525. 10.1074/jbc.M210432200.
Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA: Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA. 2006, 103: 15540-15545. 10.1073/pnas.0607518103.
Inoue M, Sato EF, Nishikawa M, Park AM, Kira Y, Imada I, Utsumi K: Mitochondrial generation of reactive oxygen species and its role in aerobic life. Curr Med Chem. 2003, 10: 2495-2505. 10.2174/0929867033456477.
Dias N, Bailly C: Drugs targeting mitochondrial functions to control tumor cell growth. Biochemical Pharmacology. 2005, 70: 1-12. 10.1016/j.bcp.2005.03.021.
Islam KN, Kayanoki Y, Kaneto H, Suzuki K, Asahi M, Fujii J, Taniguchi N: TGF-beta1 triggers oxidative modifications and enhances apoptosis in HIT cells through accumulation of reactive oxygen species by suppression of catalase and glutathione peroxidase. Free Radic Biol Med. 1997, 22: 1007-1017. 10.1016/S0891-5849(96)00493-5.
Lin SS, Huang HP, Yang JS, Wu JY, Hsia TC, Lin CC, Lin CW, Kuo CL, Gibson Wood W, Chung JG: DNA damage and endoplasmic reticulum stress mediated curcumin-induced cell cycle arrest and apoptosis in human lung carcinoma A-549 cells through the activation caspases cascade- and mitochondrial-dependent pathway. Cancer Lett. 2008, 272: 77-90. 10.1016/j.canlet.2008.06.031.
Pan JS, Hong MZ, Ren JL: Reactive oxygen species: a double-edged sword in oncogenesis. World J Gastroenterol. 2009, 15: 1702-1707. 10.3748/wjg.15.1702.
Dalton TP, Shertzer HG, Puge A: Regulation of gene expression by reactive oxygen. Pharmacol Toxicol. 1999, 39: 67-101. 10.1146/annurev.pharmtox.39.1.67.
Fruehauf JP, Meyskens FL: Reactive oxygen species: a breath of life or death?. Clin Cancer Res. 2007, 13: 789-794. 10.1158/1078-0432.CCR-06-2082.
Sauer H, Wartenberg M: Reactive oxygen species as signaling molecules in cardiovascular differentiation of embryonic stem cells and tumor-induced angiogenesis. Antioxid Redox Signal. 2005, 7: 1423-1434. 10.1089/ars.2005.7.1423.
Simon HU, Haj-Yehia A, Levi-Schaffer F: Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis. 2000, 5: 415-418. 10.1023/A:1009616228304.
Fleury C, Mignotte B, Vayssiere JL: Mitochondrial reactive oxygen species in cell death signaling. Biochimie. 2002, 84: 131-141. 10.1016/S0300-9084(02)01369-X.
Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst. 2002, 94: 504-513.
Nakano H, Nakajima A, Sakon-Komazawa S, Piao JH, Xue X, Okumura K: Reactive oxygen species mediate crosstalk between NF-kappaB and JNK. Cell Death Differ. 2006, 13: 730-737. 10.1038/sj.cdd.4401830.
Shen HM, Liu ZG: JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med. 2006, 40: 928-939. 10.1016/j.freeradbiomed.2005.10.056.
Fan J, Xu G, Nagel DJ, Hua Z, Zhang N, Yin G: A model of ischemia and reperfusion increases JNK activity, inhibits the association of BAD and 14-3-3, and induces apoptosis of rabbit spinal neurocytes. Neurosci Lett. 2010, 473: 196-201. 10.1016/j.neulet.2010.02.045.
Xiao D, Powolny AA, Singh SV: Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cells. J Biol Chem. 2008, 283: 30151-30163. 10.1074/jbc.M802529200.
Bogoyevitch MA, Kobe B: Uses for JNK: the Many and Varied Substrates of the c-Jun N-Terminal Kinases. Microbiology and Molecular Biology Reviews. 2006, 70: 1061-1095. 10.1128/MMBR.00025-06.
Davis W, Ronai Z, Tew KD: Cellular thiols and reactive oxygen species in drug-induced apoptosis. J Pharmacol Exp Ther. 2001, 296: 1-6.
Afonso V, Santos G, Collin P, Khatib AM, Mitrovic DR, Lomri N, Leitman DC, Lomri A: Tumor necrosis factor-alpha down-regulates human Cu/Zn superoxide dismutase 1 promoter via JNK/AP-1 signaling pathway. Free Radic Biol Med. 2006, 41: 709-721. 10.1016/j.freeradbiomed.2006.05.014.
Wang W, Adachi M, Kawamura R, Sakamoto H, Hayashi T, Ishida T, Imai K, Shinomura Y: Parthenolide-induced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on catalase activity. Apoptosis. 2006, 11: 2225-2235. 10.1007/s10495-006-0287-2.
Sassa H, Takaishi Y, Terada H: The triterpene celastrol as a very potent inhibitor of lipid peroxidation in mitochondria. Biochem Biophys Res Commun. 1990, 172: 890-897. 10.1016/0006-291X(90)90759-G.
Sassa H, Kogure K, Takaishi Y, Terada H: Structural basis of potent antiperoxidation activity of the triterpene celastrol in mitochondria: effect of negative membrane surface charge on lipid peroxidation. Free Radic Biol Med. 1994, 17: 201-207. 10.1016/0891-5849(94)90075-2.
Moser C, Lang SA, Stoeltzing O: Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer. Anticancer Res. 2009, 29: 2031-2042.
Chiosis G, Neckers L: Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol. 2006, 1: 279-284. 10.1021/cb600224w.
Miyata Y: Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des. 2005, 11: 1131-1138. 10.2174/1381612053507585.
Clark CB, Rane MJ, El Mehdi D, Miller CJ, Sachleben LR, Gozal E: Role of oxidative stress in geldanamycin-induced cytotoxicity and disruption of Hsp90 signaling complex. Free Radic Biol Med. 2009, 47: 1440-1449. 10.1016/j.freeradbiomed.2009.08.012.
Samuni Y, Ishii H, Hyodo F, Samuni U, Krishna MC, Goldstein S, Mitchell JB: Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs. Free Radic Biol Med. 2010, 48: 1559-1563. 10.1016/j.freeradbiomed.2010.03.001.
Bandyopadhyay U, Das D, Banerjee RK: Reactive oxygen species: oxidative damage and pathogenesis. Curr Sci India. 1999, 77: 658-666.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/170/prepub
This work was supported in part by Grant 2006CB504100 from the ''973'' Program of the Ministry of Science and Technology of China; Grant 2009ZX09301-002 from the National Key Technologies R&D Program for New Drugs; Grants 30330620 from the National Natural Science Foundation of China (to Xiaodan Yu)
The authors declare that they have no competing interests.
GC designed the study, performed most of the experiments, analyzed the data and drafted the manuscript. XY participated in the design of the study, revised the manuscript and coordinated the study. XZ participated in fluorescence microscopy. MZ participated in western blotting. XC and DW participated in cell culture and drug treatment. YW participated in discussion of the data. YX and ZD participated in sample preparation. All authors read and approved the final manuscript.